How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

585 results for

Free Thyroxine Index

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

121. Effects of short term hypothyroidism on the lipid transfer to HDL and other parameters related to lipoprotein metabolism in patients submitted to thyroidectomy for thyroid cancer. (PubMed)

a short period of overt hypothyroidism.Eighteen women (age 44 ± 11 years; body mass index 27.9 ± 5.2 kg/m2) were studied before total thyroidectomy for thyroid cancer, when they were euthyroid, and after thyroidectomy, in overt hypothyroidism for three weeks, following levothyroxine withdrawal for performance of a whole-body scan.Thyrotropin and free thyroxine confirmed hypothyroidism; low thyroglobulin and radioiodine uptake indicated near absence of thyroid tissue. LDL cholesterol (125 ± 35 vs. 167

2018 Thyroid

122. Marked improvement of thyroid function and autoimmunity by Aloe barbadensis miller juice in patients with subclinical hypothyroidism (PubMed)

subclinical hypothyroidism (SCH). Upon checking her biochemical thyroid panel when taking daily Aloe barbardensis Miller juice (ABMJ) for thyroid-unrelated reasons, she noticed a decrease in serum thyroperoxidase autoantibodies (TPOAb) and thyrotropin (TSH) and an increase in serum free thyroxine (FT4). Based on this observation, we enrolled 30 consecutive HT women with levothyroxine-untreated SCH and high TPOAb levels. All of them took ABMJ (50 ml daily) for nine months and were tested for serum TSH, FT4 (...) , free triiodothyronine (FT3) and TPOAb. Measurements were performed at baseline and at months 3 and 9. TSH, FT4 and TPOAb improved significantly already at month 3 and further (-61%, +23% and -56%) at month 9. However, FT3 decreased significantly at month 3 (-16%) with no further decrease at month 9, so that the FT4:FT3 ratio increased significantly (+33% and + 49%). At baseline, 100% of women had TSH > 4.0 mU/L and TPOAb > 400 U/ml, but frequencies fell to 0% and 37%, respectively, at month 9

Full Text available with Trip Pro

2018 Journal of clinical & translational endocrinology

123. Maternal Plasma per- and Polyfluoroalkyl Substance Concentrations in Early Pregnancy and Maternal and Neonatal Thyroid Function in a Prospective Birth Cohort: Project Viva (USA) (PubMed)

and 480 neonates in Project Viva, a longitudinal prebirth cohort in Boston, Massachusetts. We quantified six PFASs, including perfluorooctanoic acid (PFOA) and perfluorooctane sulfonate (PFOS), and maternal thyroid hormones [thyroxine (T4), Free T4 Index (FT4I), thyroid stimulating hormone (TSH)] in plasma samples collected at a median 9.6 wk gestation and neonatal T4 levels from postpartum heel sticks. We estimated associations of PFAS concentrations with thyroid hormone levels using covariate

Full Text available with Trip Pro

2018 Environmental health perspectives

124. Effect of Prepregnancy Obesity on Litter Size in Primiparous Minipigs (PubMed)

(follicle-stimulating hormone, luteinizing hormone, estradiol, progesterone, testosterone, and prolactin) and peptide hormones (insulin-like growth factor, glucagon, cortisol, growth hormone, free thyroxine, free triiodothyronine, insulin, and leptin). We also measured weight, abdominal circumference, neck circumference, and body length and then calculated the porcine obesity index. Data were analyzed by one-way ANOVA, and means were compared by least significance difference testing. Pearson correlation (...) between parameters and litter size was analyzed. Prepregnancy porcine obesity index and litter size were negatively correlated in primiparous minipigs. Litter size was influenced by luteinizing hormone, estradiol, progesterone, testosterone, prolactin, follicle-stimulating hormone, cortisol, insulin-like growth factor 1, growth hormone, free thyroxine, insulin, and leptin. In conclusion, prepregnancy obesity reduces litter size in primiparous minipigs.

Full Text available with Trip Pro

2018 Journal of the American Association for Laboratory Animal Science : JAALAS

125. Higher Prevalence of “Low T3 Syndrome” in Patients With Chronic Fatigue Syndrome: A Case–Control Study (PubMed)

integrity and nutrients influencing thyroid function and/or inflammation. Most remarkably, CFS patients exhibited similar thyrotropin, but lower free triiodothyronine (FT3) (difference of medians 0.1%), total thyroxine (TT4) (11.9%), total triiodothyronine (TT3) (12.5%), %TT3 (4.7%), sum activity of deiodinases (14.4%), secretory capacity of the thyroid gland (14.9%), 24-h urinary iodine (27.6%), and higher % reverse T3 (rT3) (13.3%). FT3 below the reference range, consistent with the "low T3 syndrome (...) ," was found in 16/98 CFS patients vs. 7/99 controls (OR 2.56; 95% confidence interval = 1.00-6.54). Most observations persisted in two sensitivity analyses with more stringent cutoff values for body mass index, high-sensitive C-reactive protein (hsCRP), and WBC. We found possible evidence of (chronic) low-grade metabolic inflammation (ferritin and HDL-C). FT3, TT3, TT4, and rT3 correlated positively with hsCRP in CFS patients and all subjects. TT3 and TT4 were positively related to hsCRP in controls. Low

Full Text available with Trip Pro

2018 Frontiers in endocrinology

126. Study of Avelumab-M3814 Combinations

of treatment at 268 days; Part B: Pre-dose up to end of treatment at 343 days ] Part A and B: Fluctuation Index of M3814 [ Time Frame: Part A: Pre-dose up to end of treatment at 268 days; Part B: Pre-dose up to end of treatment at 343 days ] Part A and B: Area Under the Plasma Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUC0-t) of M3814 [ Time Frame: Part A: Pre-dose up to end of treatment at 268 days; Part B: Pre-dose up to end of treatment at 343 days ] Part A and B: Area (...) -free Survival (PFS) Time According to RECIST v 1.1 Assessed by Investigator [ Time Frame: Part A: From baseline to planned final assessment at 305 days; Part B: From baseline to planned final assessment at 473 days ] Part A and B: Tumor size Based on Investigator Assessment According to RECIST v 1.1 [ Time Frame: From the first study intervention to planned final assessment at 508 days ] Part A and B: Overall Survival [ Time Frame: From the first study intervention to planned final assessment

2018 Clinical Trials

127. Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab

in the breast from randomization to definitive surgery. - Residual invasive breast cancer defined based on hematoxylin and eosin evaluation of the complete resected breast specimen following completion of neoadjuvant systemic therapy by pathological assessment. Residual Cancer Burden (RCB) [ Time Frame: 16 weeks from randomization ] Proportion of subjects with RCB 0-I, II or III from randomization to definitive surgery. -Residual Cancer Burden defined based on the RCB index, a component of four pathological (...) surgery). Event free survival [ Time Frame: 36 months from randomization ] Mean difference in time (in months) from randomization to any of the following events progression of disease that precludes surgery, local or distant recurrence, or death due to any cause. Invasive disease-free survival (IDFS) [ Time Frame: 33 months from surgery ] Mean difference in time (in months) from date of surgery (date of no disease) to the first documentation of invasive progressive disease or death. Overall survival

2018 Clinical Trials

128. Levothyroxine Replacement Therapy and overuse: A Timely Diagnostic Approach. (PubMed)

hypothyroidism.Among the 291 individuals, 114 became hypothyroid (group A), while 177 subjects remained euthyroid off LT4 (group B; 39.2% vs. 60.8%, p < 0.001). The groups were comparable regarding sex, family history, age, body mass index, duration of treatment, basal TSH and free thyroxine values, thyroid volume, and presence of thyroid autoantibodies. However, diffuse inhomogeneous echogenicity on ultrasound examination was significantly higher (p < 0.001) in group A.These findings suggest considerable overuse (...) factors of long-term LT4 supplementation.A prospective clinical cohort follow-up study was carried out. In 291 subjects (84% females) aged 48 ± 16 years on LT4 replacement therapy without a solid diagnosis of hypothyroidism being provided, the treatment was paused. At the beginning and after six to eight weeks of treatment discontinuation, thyrotropin (TSH) and free thyroxine levels were assessed, and thyroid ultrasound was performed. A TSH value of ≥4.5 IU/mL was considered as underlying

2018 Thyroid

129. Propensity for adverse pregnancy outcomes in African-American women may be explained by low energy expenditure in early pregnancy. (PubMed)

plethysmography and physical activity by accelerometers. Markers of metabolic health were obtained from fasting blood and urine.AA (n = 34) and white (n = 32) women were comparable in age (mean ± SEM: 27.7 ± 0.6 y), enrollment body mass index [mean ± SEM (in kg/m2): 36.9 ± 0.7], and body fat (mean ± SEM: 45.0% ± 0.6%). AA women had more fat-free mass (P = 0.01) and tended to be more insulin-resistant (homeostasis model assessment of insulin resistance, P = 0.06). Energy intake was significantly lower in AA (...) factors for disordered energy balance in AA and white women early in pregnancy.This was a cross-sectional study in 66 pregnant women with obesity, between 14 and 16 wk of gestation. Energy intake was calculated using the intake-balance method. Energy expenditure was measured in free-living conditions [total daily energy expenditure (TDEE)] over 7 d with the use of doubly labelled water and during sleep [sleeping EE (SleepEE)] in a room calorimeter. Body composition was measured by air displacement

2018 American Journal of Clinical Nutrition

130. Impaired Sensitivity to Thyroid Hormones Is Associated With Diabetes and Metabolic Syndrome. (PubMed)

Impaired Sensitivity to Thyroid Hormones Is Associated With Diabetes and Metabolic Syndrome. Diabetes prevalence and incidence increase among individuals with hypothyroidism but also among those with hyperthyroxinemia, which seems contradictory. Both high free thyroxine (fT4) and high thyroid-stimulating hormone (TSH) are present in the resistance to thyroid hormone syndrome. A mild acquired resistance to thyroid hormone might occur in the general population and be associated with diabetes. We (...) aimed to analyze the association of resistance to thyroid hormone indices (the Thyroid Feedback Quantile-based Index [TFQI], proposed in this work, and the previously used Thyrotroph T4 Resistance Index and TSH Index) with diabetes.We calculated the aforementioned resistance to thyroid hormone indices based on a U.S. representative sample of 5,129 individuals ≥20 years of age participating in the 2007-2008 National Health and Nutrition Examination Survey (NHANES). Also, to approximate TFQI, a U.S

2018 Diabetes Care

132. Genetics of Endocrine and Neuroendocrine Neoplasias (PDQ®): Health Professional Version

–56 y; P < .05) in family members diagnosed by predictive genetic testing.[ ] Nonetheless, the lag time between the diagnosis of MEN1 in an and the diagnosis of MEN1 in family members can be significant, leading to increased morbidity and mortality.[ ] This was demonstrated in a Dutch MEN1 Study Group analysis, which showed that 10% to 38% of non-index cases already had an MEN1-related manifestation at diagnosis; 4% of these individuals died of an MEN1-related cause that developed during or before (...) found that screening MEN1 patients with fluorine F 18-fludeoxyglucose positron emission tomography–computed tomography (18F-FDG PET-CT) identified those NETs with an increased malignant potential; the FDG avidity correlated with a Ki-67 index.[ ] Tumor size does seem to influence patient survival, with patients with smaller tumors having increased survival after resection.[ ] While more-extensive surgical approaches (e.g., pancreatoduodenectomy) have been associated with higher cure rates

2016 PDQ - NCI's Comprehensive Cancer Database

133. Alopecia, androgenetic - female

checking thyroid function, full blood count, and ferritin level, particularly if is suspected, the presentation is atypical, or there are features that suggest hypothyroidism or anaemia. See the CKS topics on , , and for more information. Consider basic endocrine investigations if there are features of . Initial tests may include: Free-androgen index — combined hormonal contraception should be stopped 2 months before measuring this. The test should be taken early in the morning, ideally between (...) [ ]. Considering endocrine investigations This recommendation is based on expert consensus that an extensive endocrinological workup is not necessary in most women with androgenetic alopecia, but that basic endocrine investigations should be carried out if the woman has features suggestive of androgen excess [ ; ; ; ]. Recommended tests are measurement of the free-androgen index (FAI) and prolactin level. However, previous expert reviewers of this CKS topic differed on their opinion of the initial endocrine

2016 NICE Clinical Knowledge Summaries

134. Prevention of Diabetes in Overweight/Obese Preadolescent Children

, and triglycerides), glucose, insulin, and hemoglobin A1c, cytokines (e.g. tumor necrosis factor alpha and IL-6) adipokines (e.g leptin and adiponectin), hepatokines (fetuin-A and fibroblast growth factor-21), liver enzymes (alanine aminotransferase, aspartate aminotransferase and gamma-glutamyl transferase), C-reactive protein, thyroid hormones (thyroid stimulating hormone, triiodothyronine and free thyroxine), urea, bilirubin and uric acid Other Outcome Measures: Confounding variable: puberty stage [ Time (...) aerobic activities, and strength exercises Outcome Measures Go to Primary Outcome Measures : Insulin resistance [ Time Frame: Baseline and at the end of the 22 weeks of intervention ] The Homeostasis model assessment index will be calculated as fasting insulin concentration (microU/mL) x fasting glucose concentration (mmol/L)/22.5. microRNA expression in circulating exosomes and in blood peripheral mononuclear cells [ Time Frame: Baseline and at the end of the 22 weeks of intervention ] The expression

2017 Clinical Trials

135. Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors

[ Time Frame: Approximately every 12 weeks and/or re-staging through study completion (up to 2 years) ] Secondary Outcome Measures : Treatment-related adverse events [ Time Frame: Continuous, at minimum every 3 weeks until study completion (up to 2 years) ] Progression free survival (PFS) of pembrolizumab in combination with lanreotide depot in subjects with GEP-NETs. [ Time Frame: From date of randomization until the date of first documented progression or date of death from any cause (whichever (...) within ≤ 7 days prior to the first dose of study drug, for women of childbearing potential only. Female subjects agree to use two birth control methods, be surgically sterile, or abstain from heterosexual activity for the course of the study through 120 days after the last dose of study drug. Male subjects agree to use an adequate method of contraception for the course of the study through 120 days after the last dose of study drug. Exclusion Criteria: Tumor mitotic rate >20/10 hpf and/or Ki67 index

2017 Clinical Trials

136. Theophylline Treatment for Pseudohypoparathyroidism

cirrhosis and acute hepatitis (AST or ALT >3x upper limit of normal) Congestive heart failure Current cigarette use or alcohol abuse Pregnancy or intention to become pregnant during the next year Untreated hypothyroidism (defined as free thyroxine below the lower limit of normal) Active peptic ulcer disease Current use of medications known to effect theophylline levels History of hypersensitivity to theophylline or other medication components History of Major Depressive Disorder in the past 2 years (...) in children and young adults with PHP. Theophylline is a non-selective PDE inhibitor that is generically available and has a long history of use in pediatric patients, making it an ideal drug for re-purposing in youth with PHP. Furthermore, the pharmacokinetics of theophylline are well understood and serum drug levels are easily measured. The investigators primary outcome is change in body mass index. Secondary outcome measures include change in glucose tolerance and HRT dose. Anticipating a 10% dropout

2017 Clinical Trials

137. Study of Y90-Radioembolization With Nivolumab in Asians With Hepatocellular Carcinoma

with nivolumab To assess progression free survival and overall survival when RE is combined with nivolumab To assess the quality of life using the FACT-HEP score and EORTC QLQ-C30 To assess the safety and tolerability of the combination of RE and nivolumab Exploratory objectives To evaluate the relationship between tumor biopsy PD-L1 expression and response to treatment with Y90 radioembolization in combination with nivolumab To assess relationship between blood lymphocyte (e.g., T cell) activation (...) of Nivolumab ] Duration of Response [ Time Frame: From date of first assessment of CR or PR until the first date that progressive disease or death is documented, up to 2 years ] Time to Progression [ Time Frame: From date of first dose with Y90 RE until the first date that progressive disease is documented, up to 12 weeks after last dose of Nivolumab ] Progression Free Survival [ Time Frame: From date of first dose with Y90 RE until tumour progression, or death from any cause, up to 12 weeks after last

2017 Clinical Trials

138. Efficacy of Fenugreek Seed and Lespedeza Cuneata in TDS

as levels of serum total testosterone and free testosterone. Secondary efficacy measurements included changes from baseline in the number of 'yes' answers on the Androgen Deficiency in the Aging Male questionnaire (ADAM), levels of serum total cholesterol, HDL-C, LDL-C, triglyceride, perceived stress scale (PSS-10), all domain scores of the International Index of Erectile Function (IIEF), as well as changes in body composition. Condition or disease Intervention/treatment Phase Hypogonadism Drug: TFG (...) index ≥ 45 kg/m2, HBsAg (hepatitis B surface antigen) positive, prostate specific antigen (PSA) ≥ 4.0 ng/ml, cardiac failure, or a history of alcoholism or substance abuse. Patients who had taken PDE5 inhibitors, TRT, anti-androgen, statins, fibrates, niacin, steroid, fish oil, colestin, fiber-based laxatives, phytosterol margarines, anti-diabetics, anti-platelet, thyroxine, diuretics, or beta-blockers were also excluded. Contacts and Locations Go to Information from the National Library of Medicine

2017 Clinical Trials

139. The Role of Thyroid Status in Regulating Brown Adipose Tissue Activity, White Adipose Tissue Partitioning and Resting Energy Expenditure

the relationship between brown adipose tissue (BAT) volume/activity, white adipose tissue (WAT) partitioning and basal metabolic rate (BMR) in hyperthyroid patients transitioning to euthyroidism via antithyroid drugs. To compare euthyroid outcomes (BAT, WAT, BMR, body composition, body weight and insulin resistance) achieved by hypothalamus-pituitary-thyroid (HPT) set point vs. normal ranges of plasma free thyroxine 4 (FT4) and throxine stimulating hormone (TSH). Condition or disease Intervention/treatment (...) for: (AHRQ) related information: Groups and Cohorts Go to Intervention Details: Drug: carbimazole (CMZ) or thiamazole (TMZ) CMZ or TMZ will be used to treat the hyperthyroidism till the FT4/TSH is in normal range. Outcome Measures Go to Primary Outcome Measures : Thyroid function test (serum free thyroxine (FT4) and serum thyroid stimulating hormone (TSH). [ Time Frame: 6 months of treatment with an anti-thyroid drug ] This observation supports the concept of a unique set point in FT4 and TSH for any

2017 Clinical Trials

140. Effect of Roux-en-Y gastric bypass on thyroid function in euthyroid patients with obesity and type 2 diabetes. (PubMed)

Effect of Roux-en-Y gastric bypass on thyroid function in euthyroid patients with obesity and type 2 diabetes. The impact of bariatric surgery on thyroid hormone levels is poorly understood.To investigate changes in serum-free thyroxine (FT4) and thyroid-stimulating hormone (TSH) after Roux-en-Y gastric bypass (RYGB) in euthyroid patients with obesity and type 2 diabetes.University Hospital, China.Eighty-one euthyroid Chinese patients with obesity and type 2 diabetes who underwent RYGB, and 20 (...) healthy volunteers were enrolled in this retrospective study. Participants were evaluated for changes in anthropometric parameters, metabolic indexes, FT4, and TSH at baseline and 6 months after surgery. Multiple linear regression analysis was used to identify factors that could predict changes in FT4 and TSH.Mean FT4 levels decreased from 16.26-14.59 pmol/L (P<.01), while TSH levels decreased significantly (2.19±1.09 mIU/L versus 1.97±1.12 mIU/L, P = .027) 6 months postsurgery. Multiple linear

2017 Surgery for Obesity and Related Diseases

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>